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L E T T E R  T O  T H E  E D I T O R
Extent of inflammation in severe nasal polyposis and effect of 
sinus surgery on inflammation
To the editor:
Chronic rhinosinusitis with nasal polyps (CRSwNP) is, in the Western 
world, mainly characterized by an eosinophilic type 2 inflammation 
with elevated levels of immunoglobulin E (IgE), eosinophil cationic 
protein (ECP) and interleukin (IL)-5.1 A subgroup of CRSwNP patients 
often with comorbid asthma and aspirin-exacerbated respiratory 
disease responds poorly to treatment and relapse after surgery.1 
A more extensive type of surgery in CRSwNP has previously been 
described to be successful to prevent nasal polyp relapse,2,3 also in-
cluding the frontal sinuses into the procedure. Our group recently 
showed that the reboot technique, with the focus on the removal 
of the sinus mucosa down to the periosteum in all affected sinuses, 
with or without a Draf III procedure, reduced relapse rates compared 
to conventional mucosa-sparing surgery compared to conventional 
mucosa-sparing surgery.4 The aim of this study was to investigate 
the extent of inflammation in the sinuses associated with nasal poly-
posis and to understand the impact of reboot surgery on local and 
systemic inflammatory markers. For information on the reboot tech-
nique and postoperative treatment, see the methodological section 
in the Appendix S1.
During reboot surgery, tissue samples, both polyps and non-pol-
ypoid sinus mucosa, from the different sinuses, polyps in the nose 
and a biopsy from the middle turbinate were collected (in total 76 
samples, for numbers of samples from each location please see 
Table S2). Inferior turbinate biopsies from healthy patients were 
used as controls. Twenty-one patients undergoing reboot surgery 
were followed up for 1 year, and nasal secretions and serum samples 
were collected prior to surgery and after 1 year. Nasal secretions 
and serum from healthy patients participating in the GA2LEN co-
hort5 were used as controls. Tissue, nasal secretions and serum were 
analysed for type 2 inflammatory markers.
The study demonstrated that IgE, ECP and IL-5 were elevated in 
all sinuses compared to controls, and IgE and ECP were also elevated 
in the middle turbinate of CRSwNP patients compared to controls. 
The inflammation was equally present in polyps and in non-polypoid 
mucosa (Figure 1 and Tables S2 and S3). There was no significant dif-
ference between single sinuses for any of the cytokines; moreover, 
paired analysis between polypoid and non-polypoid tissue within 
the same sinus of individual patients did not show any significant 
difference.
CRSwNP patients at inclusion had elevated levels of type 2 in-
flammatory markers compared to controls. Reboot surgery reduced 
levels of IgE, ECP and IL-5 in nasal secretions, a reduction that per-
sisted 12 months after surgery; however, type 2 markers in nasal 
secretions did not reach levels of controls (Table 1). MPO and IL-17 
did not show a significant reduction.
No change was seen in type 2 markers in serum (Table S4). For 
pre-and postoperative symptom scores and clinical outcome, please 
see the results part in Appendix S1 and Figure S1.
Our results show that the inflammation in CRSwNP is not lim-
ited to the polyps themselves but is equally present in the non-pol-
ypoid sinus mucosa. This non-polypoid mucosa is not addressed 
during conventional sinus surgery and might maintain exten-
sive inflammation and inflammatory triggers leading to relapse. 
Moreover, the inflammation is widespread and includes all the dif-
ferent sinuses. Computed tomography studies after treatment with 
biologicals have previously shown a reduction of opacification in all 
sinuses (total Lund-Mackay scores) in severe CRSwNP patients6,7 
supporting our notion of widespread disease. These findings sup-
port the rationale of a complete surgery, the reboot approach, to 
prevent relapse of disease in severe CRSwNP patients. Type 2 in-
flammatory markers in nasal secretions were reduced after reboot 
surgery, at least for 12 months after surgery, but did not reach the 
same levels as in healthy controls. This reduction of type 2 mark-
ers resembles findings from CRSwNP treated subjects with a novel 
monoclonal antibody, dupilumab.8 Our group has previously shown 
that the inferior turbinates in CRSwNP patients contain elevated 
levels of type 2 inflammatory markers.9 Here, we show that the 
middle turbinates also express elevated levels of IgE and ECP, how-
ever, without forming nasal polyps. The persistent inflammation in 
the middle and inferior turbinates may explain why inflammatory 
levels in nasal secretions do not decrease to the same levels as in 
healthy controls after surgery. Extensive sinus surgery is debated, 
and removing all mucosa down to the periosteum raises concerns 
of causing severe complications and scar formation postopera-
tively. However, in our patients, healthy mucosa covered the sinus 
walls within a period of 4-6 weeks postoperatively, and this mucosa 
showed all elements of normal structured ciliated epithelium with 
activated goblet cells.4 This is a small study of a novel surgical ap-
proach, and our findings need to be confirmed in a larger setting. 
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In conclusion, the inflammation in CRSwNP is extensive and in-
volves polyps and non-polypoid mucosa. Reboot surgery decreases 
inflammatory markers 12 months after surgery. We propose that 
our results should be taken into consideration when planning the 
extent of surgery in severe CRSwNP patients. The reboot tech-
nique should however be reserved for massive, difficult to control 
type 2 CRSwNP patients and be performed by an experienced sur-
geon to avoid complications.
F I G U R E  1   A, Levels of IgE, ECP and IL-5 in sinus mucosa, both polyps and non-polypoid sinus mucosa, from the different sinuses, 
nasal polyp, middle turbinate and controls. The boxes indicate the median and IQR and whiskers min; max; Kruskal-Wallis test with Dunn's 
multiple comparison. B, Levels of IgE, ECP and IL-5 in polyps (P), non-polypoid sinus mucosa (M) and controls (C). The boxes indicate the 
median and whiskers IQR; Kruskal-Wallis test with Dunn's multiple comparison. ***P ≤ .001, **P ≤ .01, *P < .05, ns; not significant. ECP, 
eosinophil cationic protein; ES, ethmoid sinus; MS, maxillary sinus; SS, sphenoid sinus; FS, frontal sinus; NP, nasal polyp; MT, middle turbinate
TA B L E  1   Levels of type 2 markers in nasal secretions in CRSwNP at inclusion and at 12 mo' follow-up and in controls
Nasal secretions Inclusion 12 mo Controls P-valuea P-valuea P-valueb







53.3 (8.8;185.8) 20.6 (4.9;96.11) 2.8 (1.7;4.7) .0002* .006* .03*
ECP μg/L
median (IQR)
1030 (182.3;1650) 482.1 (126;1288) 42.4 (24.2;243.7) .002* .04* .04*
IL-5 pg/mL median 
(IQR)
33.7 (2.4;309.2) 5.1 (2.1;62.6) Not detectable — — .04*
MPO pg/mL
median (IQR)
9.7 × 106 
(1.936 × 106;29.362 × 106)
10.127 × 106
(3.9 × 106;19.6 × 106)
2826 (244.2;6333) <.0001 <.0001 .6
IL-17 pg/mL
median (IQR)
11.3 (3.3;22.7) 9.8 (4.1;20.6) 27.8 (14.4;40.58) .14 .15 .7
Note: P-value obtained by Kruskal-Wallis test with Dunn's multiple comparison (a) and Wilcoxon matched pair signed rank test (b). Significant P-values 
are indicated with (*).
Abbreviations: 12 mo, 12 months; C, control; ECP, eosinophil cationic protein; I, inclusion.
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